Sugiyama Y, Aihara M, Shibamori M, Deguchi K, Imagawa K, Kikuchi M, Momota H, Azuma T, Okada H, Alper O
Viral Diseases Research Division, Tokushima Research Institute, Otsuka Pharmaceutical Co., Ltd.
Jpn J Cancer Res. 1992 Jun;83(6):563-7. doi: 10.1111/j.1349-7006.1992.tb00126.x.
With the aim of developing an effective cancer immunotherapy for common epithelial cancer, a new class of bifunctional antibody (BFA) was developed; one arm of this BFA recognized c-erbB-2 gene product, and the other arm recognized CD3 epsilon, a T-cell specific surface antigen. Application of this BFA with human peripheral blood lymphocytes exhibited specific anti-tumor activity in vitro on a breast tumor cell line, ZR-75-1, which expressed abundant c-erbB-2 gene product on its cell surface. These results indicate that BFA recognizing an oncogene product on cell surface is a potential new agent for cancer immunotherapy.
为了开发一种针对常见上皮癌的有效癌症免疫疗法,研发了一类新型双功能抗体(BFA);该BFA的一个臂识别c-erbB-2基因产物,另一个臂识别CD3 ε,一种T细胞特异性表面抗原。将这种BFA与人外周血淋巴细胞一起应用,在体外对乳腺癌细胞系ZR-75-1表现出特异性抗肿瘤活性,该细胞系在其细胞表面表达丰富的c-erbB-2基因产物。这些结果表明,识别细胞表面癌基因产物的BFA是一种潜在的癌症免疫治疗新药物。